Table 1 Characteristics of advanced NSCLC patients in the training and validation cohorts
Characteristic | Training Cohort | P Value | Validation Cohort1 | P Value | Validation Cohort2 | P Value | |||
|---|---|---|---|---|---|---|---|---|---|
BM = 208 | NonBM = 168 | BM = 82 | NonBM = 79 | BM = 19 | NonBM = 46 | ||||
Sex | 0.41 | 0.19 | 0.52 | ||||||
Male | 111 (29.52) | 96 (25.53) | 49 (30.43) | 39 (24.22) | 12 (18.46) | 25 (38.46) | |||
Female | 97 (25.80) | 72 (19.15) | 33 (20.50) | 40 (24.85) | 7 (10.77) | 21 (32.31) | |||
Age | 57 ± 9.92 | 58 ± 9.86 | 0.97 | 57 ± 9.41 | 58 ± 11.06 | 0.61 | 64.±12.00 | 63 ± 9.16 | 0.23 |
Smoking | 0.19 | 0.36 | 0.54 | ||||||
Current or Former | 79 (21.01) | 75 (19.95) | 37 (22.98) | 30 (18.63) | 4 (6.15) | 13 (20.00) | |||
Never | 129 (34.31) | 93 (24.73) | 45 (27.95) | 49 (30.44) | 15 (23.08) | 33 (50.77) | |||
Pathology | 0.5 | 0.81 | 0.96 | ||||||
Adenocarcinoma | 176 (46.81) | 126 (33.51) | 63 (39.13) | 57 (35.40) | 16 (24.62) | 40 (61.54) | |||
Squamous Cell Carcinoma | 17 (4.52) | 40 (10.64) | 9 (5.59) | 18 (11.18) | 3 (4.62) | 5 (7.69) | |||
Others | 15 (3.99) | 2 (0.53) | 10 (6.21) | 4 (2.49) | 0 (0.00) | 1 (1.54) | |||
CEA | 30.65 ± 83.80 | 19.15 ± 60.17 | 0.12 | 14.32 ± 27.02 | 10.15 ± 18.41 | 0.26 | 53.34 ± 93.58 | 8.19 ± 14.98 | 0.003 |
CYFRA21-1 | 5.19 ± 8.18 | 5.98 ± 9.24 | 0.39 | 5.09 ± 6.88 | 4.93 ± 4.00 | 0.86 | 6.78 ± 7.15 | 6.20 ± 15.56 | 0.84 |
NSE | 11.87 ± 9.03 | 12.34 ± 5.77 | 0.56 | 12.20 ± 8.69 | 12.03 ± 3.79 | 0.87 | 17.60 ± 7.56 | 13.31 ± 8.94 | 0.06 |
AFP | 1.58 ± 2.00 | 1.88 ± 2.43 | 0.19 | 1.58 ± 1.60 | 2.36 ± 4.18 | 0.13 | 1.85 ± 1.58 | 1.54 ± 1.71 | 0.50 |
Thickness | 1.77 ± 1.46 | 1.23 ± 0.80 | < 0.001 | 1.36 ± 1.04 | 1.10 ± 0.47 | 0.045 | 1.53 ± 0.94 | 1.18 ± 0.38 | 0.04 |
Spacing | 0.75 ± 0.06 | 0.77 ± 0.06 | 0.006 | 0.76 ± 0.06 | 0.76 ± 0.06 | 0.57 | 0.71 ± 0.03 | 0.69 ± 0.06 | 0.05 |